Literature DB >> 33444547

Immune Responses of Alphavirus Vaccination in Patients with HPV-Induced Cancers.

Kenneth Lundstrom1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33444547      PMCID： PMC7854350          DOI： 10.1016/j.ymthe.2021.01.008

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  6 in total

1.  Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.

Authors:  Toos Daemen; Annelies Riezebos-Brilman; Laura Bungener; Joke Regts; Bert Dontje; Jan Wilschut
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641

2.  GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles.

Authors:  Annelies Jorritsma-Smit; Coba J van Zanten; Jolande Schoemaker; Janneke J M Meulenberg; Daan J Touw; Jos G W Kosterink; Hans W Nijman; Toos Daemen; Derk P Allersma
Journal:  Eur J Pharm Sci       Date:  2019-10-25       Impact factor: 4.384

3.  Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.

Authors:  Paul F McKay; Kai Hu; Anna K Blakney; Karnyart Samnuan; Jonathan C Brown; Rebecca Penn; Jie Zhou; Clément R Bouton; Paul Rogers; Krunal Polra; Paulo J C Lin; Christopher Barbosa; Ying K Tam; Wendy S Barclay; Robin J Shattock
Journal:  Nat Commun       Date:  2020-07-09       Impact factor: 14.919

4.  First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.

Authors:  Fenne L Komdeur; Amrita Singh; Stephanie van de Wall; Janneke J M Meulenberg; Annemarie Boerma; Baukje Nynke Hoogeboom; Sterre T Paijens; Cesar Oyarce; Marco de Bruyn; Ed Schuuring; Joke Regts; Ruben Marra; Naomi Werner; Jessica Sluis; Ate G J van der Zee; Jan C Wilschut; Derk P Allersma; Coba J van Zanten; Jos G W Kosterink; Annelies Jorritsma-Smit; Refika Yigit; Hans W Nijman; Toos Daemen
Journal:  Mol Ther       Date:  2020-11-05       Impact factor: 11.454

5.  Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens.

Authors:  Stephanie van de Wall; Karl Ljungberg; Peng Peng Ip; Annemarie Boerma; Maria L Knudsen; Hans W Nijman; Peter Liljeström; Toos Daemen
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

Review 6.  Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2020-11-18       Impact factor: 5.048
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.